Ibio Inc Stock News

Out of thousands of stocks that are currently traded on the market, it is difficult to identify those that will really generate strong returns. Hedge funds and institutional investors spend millions

One of the more intriguing high-risk, high-reward ideas in the Covid-19 space, IBIO stock had an opportunity to distinguish itself. But with the vaccine race heating up, the dangers outweigh the possi

iBio reports impressive Q1 results as biotech companies see a strong rally this year. Here's the latest on IBIO stock.

iBio's first-quarter included steep losses and not much else. If IBIO stock is to rise to $2, investors need some good news to chew on.

The latest in IBIO news: stay away from IBIO stock, which has over-issued shares to survive. The stock remains below the average issue price.

iBio, Inc. (iBio) CEO Thomas Isett on Q1 2021 Results - Earnings Call Transcript

BRYAN, Texas, Nov. 16, 2020 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a biotech innovator and biologics contract manufacturing organization, today announced its fi

The latest iBio news isn't good. It's taken too long for IBIO to develop a coronavirus vaccine and now the opportunity has disappeared.

iBio has a huge vertical farming facility and a couple of high-potential vaccine candidates, which should offer hope to IBIO stock holders. The post Two Covid-19 Vaccine Candidates Hold Promise for iB

Investor interest a unique production system isn't enough to make buying IBIO stock a worthwhile move at this time. The post iBio Remains a Biotech Sideline Play as Covid Rages appeared first on Inves

BRYAN, Texas, Nov. 05, 2020 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a biotech innovator and biologics contract manufacturing organization, announced today that i

IBIO stock has been hit hard by its apparent failure to produce the first COVID-19 vaccine, but that's a simplistic view of iBio's prospects. The post First to COVID-19 Vaccine or Not, iBio Is a Smart

- Brings >20 Years of Global Biotech Operations and Business Development Experience - - Brings >20 Years of Global Biotech Operations and Business Development Experience -

Yes, I will continue to root for Ibio in its fight to make a huge leap with its Covid-19 efforts. But where my investment dollar is concerned, it'll be from the sidelines.

The time to make money by investing in iBio is over. Here's why that's good news.